Net Income

KBRA rates a $328M mortgage trust with significant 'non-prime' loans, signaling a boom in a market segment that balances risk with investor demand.

A shocking 9,000% rise in senior overdose deaths sparks a new video initiative. But is education enough to combat a crisis hidden in plain sight?

A 150-year-old agricultural giant is pivoting its strategy, using a sophisticated data model to link sustainability directly to its bottom line.

With a new CEO, Menagerie Cellars is doubling down on its blend of luxury wine and conservation. Can this purpose-driven model scale in a tough market?

After a costly restatement process, Next Bridge Hydrocarbons shifts its drilling focus. But can a new strategy resolve its unique shareholder crisis?

Hong Kong's JM Group raised $15M in a wild NYSE debut. We look past the volatility to see what this IPO reveals about global supply chains and risk.

Lion Group's $8M Bitcoin purchase highlights a growing corporate trend, but a plunging stock price reveals the immense risks of digital asset treasuries.

NextNRG's latest healthcare microgrid deal reveals a high-stakes strategy: turning regulatory pressure into long-term, AI-driven recurring revenue.

GoPro is turning user videos into a new revenue stream for the AI economy. Can this bold strategic shift save the company, or will it get lost in the ethical fog?

Illumina's new partnership with MyOme targets a $200B healthcare savings prize. But can AI-driven genomics overcome the hurdles to deliver resilient returns?

MMTEC dodged delisting, but a one-year Nasdaq monitor and a history of reverse splits raise questions about its long-term viability on US exchanges.

TIME's honor for AI's creators reveals a hidden truth: the digital revolution's massive energy and hardware needs are supercharging the race for minerals.

Early results for INT230-6 show 50% fewer severe side effects, raising hopes for a treatment that could eliminate the toxic 'red devil' chemo.

Adagio Medical lands ex-Medtronic exec Sean Salmon. His mission: drive its novel cryoablation tech to disrupt the competitive cardiac arrhythmia market.

Astellas Pharma's new deal with venture studio Autobahn Labs isn't just a partnership; it's a strategic overhaul of the R&D pipeline. Here's why.

Cadrenal Therapeutics acquires a novel Phase 2 drug for a deadly clotting disorder, a strategic move targeting an underserved $1 billion market.

A Delaware Supreme Court ruling revives a massive liability risk for Loews, extending a seven-year legal battle over its 2018 Boardwalk Pipelines deal.

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

As lithium fire risks escalate, a small-cap firm's live EV burn demo in Houston draws industry giants, signaling a pivotal moment for safety tech.

How TerraVest's aggressive acquisition spree is reshaping industrial markets and delivering substantial returns to shareholders. Dive into the strategy.